CARHSP1

Across TCGA pan-cancer cohorts, CARHSP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CARHSP1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CARHSP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CARHSP1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where CARHSP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.368	0.713	<.001	29	view →
HNSC	DFS	Quartile	All	0.894	0.607	.006	27	view →
CCRCC	OS	Quartile	II,III,IV	0.985	0.104	.024	16	view →
PDAC	OS	Median	All	0.493	0.663	.027	5	view →
UCEC	DFS	Median	II,III,IV	0.867	0.534	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CARHSP1–GBM (OS)

Open the GBM breakdown →